Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $20.0 million.

  • Indivior Pharmaceuticals' Capital Expenditures rose 18571.43% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.0 million, marking a year-over-year increase of 13200.0%. This contributed to the annual value of $29.0 million for FY2024, which is 26250.0% up from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Capital Expenditures stood at $20.0 million, which was up 18571.43% from $17.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Capital Expenditures ranged from a high of $20.0 million in Q3 2025 and a low of -$2.0 million during Q3 2022
  • For the 4-year period, Indivior Pharmaceuticals' Capital Expenditures averaged around $6.6 million, with its median value being $5.0 million (2025).
  • As far as peak fluctuations go, Indivior Pharmaceuticals' Capital Expenditures changed by 0.0% in 2023, and later surged by 50000.0% in 2024.
  • Over the past 4 years, Indivior Pharmaceuticals' Capital Expenditures (Quarter) stood at $9.0 million in 2022, then surged by 33.33% to $12.0 million in 2023, then surged by 33.33% to $16.0 million in 2024, then increased by 25.0% to $20.0 million in 2025.
  • Its Capital Expenditures was $20.0 million in Q3 2025, compared to $17.0 million in Q2 2025 and $5.0 million in Q1 2025.